Absolute Neutrophil Count in the Peripheral Blood Predicts Prognosis in Lung Cancer Patients Treated with Anlotinib
Anlotinib is a multi-targeted tyrosine kinase inhibitor that inhibits tumor angiogenesis and cell proliferation. It is widely used as a third-line therapy for lung cancer. However, reliable prognostic biomarkers for predicting the efficacy of anlotinib are lacking. We conducted a retrospective study...
Saved in:
| Published in | Cancer management and research Vol. 13; pp. 3619 - 3627 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New Zealand
Dove Medical Press Limited
01.01.2021
Taylor & Francis Ltd Dove Dove Medical Press |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Anlotinib is a multi-targeted tyrosine kinase inhibitor that inhibits tumor angiogenesis and cell proliferation. It is widely used as a third-line therapy for lung cancer. However, reliable prognostic biomarkers for predicting the efficacy of anlotinib are lacking. We conducted a retrospective study to investigate the prognostic value of serological inflammatory biomarkers in anlotinib treatment.
Patients with advanced lung cancer treated with anlotinib monotherapy were enrolled. Cox regression was conducted to analyze the significant factors related to progression-free survival (PFS) and overall survival (OS). The objective response rate (ORR) was compared based on the median cut-off value of the significant inflammation index. Meanwhile, we created survival curves to compare the two groups and performed receiver operating characteristic curve analysis to assess the predictive ability of the inflammation index.
Among a total of 71 patients, the median PFS was 5.5 months and the median OS was 9.5 months. The ORR and disease control rate were 16.9% and 84.5%, respectively. According to univariate and multivariate analyses, absolute neutrophil count (ANC) was the only indicator associated with both PFS (hazard ratio [HR] =1.095, 95% confidence interval [CI] 1.030-1.163, P=0.003) and OS (HR=1.057, 95% CI 1.003-1.113, P=0.037). In the group with ANC ≥4.58, the ORR was relatively lower (8.1% vs 26.5%, P=0.057), but not statistically significant; PFS and OS were relatively shorter (median PFS 5.0 [95% CI 4.4-9.6] vs 7.0 months [95% CI 4.4-5.7], P=0.024 and median OS 7.3 [95% CI 4.7-10.0] vs 17.6 months [95% CI 12.3-22.9], P < 0.001). ANC had a relatively high discriminatory ability to predict 10-month survival, with an area under the curve of 0.729, sensitivity of 82.5%, and specificity of 67.7%.
Elevated pre-treatment ANC was associated with a poor prognosis. Patients with lower peripheral blood levels of ANC might benefit from anlotinib. |
|---|---|
| AbstractList | Purpose: Anlotinib is a multi-targeted tyrosine kinase inhibitor that inhibits tumor angiogenesis and cell proliferation. It is widely used as a third-line therapy for lung cancer. However, reliable prognostic biomarkers for predicting the efficacy of anlotinib are lacking. We conducted a retrospective study to investigate the prognostic value of serological inflammatory biomarkers in anlotinib treatment. Patients and Methods: Patients with advanced lung cancer treated with anlotinib monotherapy were enrolled. Cox regression was conducted to analyze the significant factors related to progression-free survival (PFS) and overall survival (OS). The objective response rate (ORR) was compared based on the median cut-off value of the significant inflammation index. Meanwhile, we created survival curves to compare the two groups and performed receiver operating characteristic curve analysis to assess the predictive ability of the inflammation index. Results: Among a total of 71 patients, the median PFS was 5.5 months and the median OS was 9.5 months. The ORR and disease control rate were 16.9% and 84.5%, respectively. According to univariate and multivariate analyses, absolute neutrophil count (ANC) was the only indicator associated with both PFS (hazard ratio [HR] =1.095, 95% confidence interval [CI] 1.030– 1.163, P=0.003) and OS (HR=1.057, 95% CI 1.003– 1.113, P=0.037). In the group with ANC ≥ 4.58, the ORR was relatively lower (8.1% vs 26.5%, P=0.057), but not statistically significant; PFS and OS were relatively shorter (median PFS 5.0 [95% CI 4.4– 9.6] vs 7.0 months [95% CI 4.4– 5.7], P=0.024 and median OS 7.3 [95% CI 4.7– 10.0] vs 17.6 months [95% CI 12.3– 22.9], P < 0.001). ANC had a relatively high discriminatory ability to predict 10-month survival, with an area under the curve of 0.729, sensitivity of 82.5%, and specificity of 67.7%. Conclusion: Elevated pre-treatment ANC was associated with a poor prognosis. Patients with lower peripheral blood levels of ANC might benefit from anlotinib. Anlotinib is a multi-targeted tyrosine kinase inhibitor that inhibits tumor angiogenesis and cell proliferation. It is widely used as a third-line therapy for lung cancer. However, reliable prognostic biomarkers for predicting the efficacy of anlotinib are lacking. We conducted a retrospective study to investigate the prognostic value of serological inflammatory biomarkers in anlotinib treatment.PURPOSEAnlotinib is a multi-targeted tyrosine kinase inhibitor that inhibits tumor angiogenesis and cell proliferation. It is widely used as a third-line therapy for lung cancer. However, reliable prognostic biomarkers for predicting the efficacy of anlotinib are lacking. We conducted a retrospective study to investigate the prognostic value of serological inflammatory biomarkers in anlotinib treatment.Patients with advanced lung cancer treated with anlotinib monotherapy were enrolled. Cox regression was conducted to analyze the significant factors related to progression-free survival (PFS) and overall survival (OS). The objective response rate (ORR) was compared based on the median cut-off value of the significant inflammation index. Meanwhile, we created survival curves to compare the two groups and performed receiver operating characteristic curve analysis to assess the predictive ability of the inflammation index.PATIENTS AND METHODSPatients with advanced lung cancer treated with anlotinib monotherapy were enrolled. Cox regression was conducted to analyze the significant factors related to progression-free survival (PFS) and overall survival (OS). The objective response rate (ORR) was compared based on the median cut-off value of the significant inflammation index. Meanwhile, we created survival curves to compare the two groups and performed receiver operating characteristic curve analysis to assess the predictive ability of the inflammation index.Among a total of 71 patients, the median PFS was 5.5 months and the median OS was 9.5 months. The ORR and disease control rate were 16.9% and 84.5%, respectively. According to univariate and multivariate analyses, absolute neutrophil count (ANC) was the only indicator associated with both PFS (hazard ratio [HR] =1.095, 95% confidence interval [CI] 1.030-1.163, P=0.003) and OS (HR=1.057, 95% CI 1.003-1.113, P=0.037). In the group with ANC ≥4.58, the ORR was relatively lower (8.1% vs 26.5%, P=0.057), but not statistically significant; PFS and OS were relatively shorter (median PFS 5.0 [95% CI 4.4-9.6] vs 7.0 months [95% CI 4.4-5.7], P=0.024 and median OS 7.3 [95% CI 4.7-10.0] vs 17.6 months [95% CI 12.3-22.9], P < 0.001). ANC had a relatively high discriminatory ability to predict 10-month survival, with an area under the curve of 0.729, sensitivity of 82.5%, and specificity of 67.7%.RESULTSAmong a total of 71 patients, the median PFS was 5.5 months and the median OS was 9.5 months. The ORR and disease control rate were 16.9% and 84.5%, respectively. According to univariate and multivariate analyses, absolute neutrophil count (ANC) was the only indicator associated with both PFS (hazard ratio [HR] =1.095, 95% confidence interval [CI] 1.030-1.163, P=0.003) and OS (HR=1.057, 95% CI 1.003-1.113, P=0.037). In the group with ANC ≥4.58, the ORR was relatively lower (8.1% vs 26.5%, P=0.057), but not statistically significant; PFS and OS were relatively shorter (median PFS 5.0 [95% CI 4.4-9.6] vs 7.0 months [95% CI 4.4-5.7], P=0.024 and median OS 7.3 [95% CI 4.7-10.0] vs 17.6 months [95% CI 12.3-22.9], P < 0.001). ANC had a relatively high discriminatory ability to predict 10-month survival, with an area under the curve of 0.729, sensitivity of 82.5%, and specificity of 67.7%.Elevated pre-treatment ANC was associated with a poor prognosis. Patients with lower peripheral blood levels of ANC might benefit from anlotinib.CONCLUSIONElevated pre-treatment ANC was associated with a poor prognosis. Patients with lower peripheral blood levels of ANC might benefit from anlotinib. Purpose: Anlotinib is a multi-targeted tyrosine kinase inhibitor that inhibits tumor angiogenesis and cell proliferation. It is widely used as a third-line therapy for lung cancer. However, reliable prognostic biomarkers for predicting the efficacy of anlotinib are lacking. We conducted a retrospective study to investigate the prognostic value of serological inflammatory biomarkers in anlotinib treatment. Patients and Methods: Patients with advanced lung cancer treated with anlotinib monotherapy were enrolled. Cox regression was conducted to analyze the significant factors related to progression-free survival (PFS) and overall survival (OS). The objective response rate (ORR) was compared based on the median cut-off value of the significant inflammation index. Meanwhile, we created survival curves to compare the two groups and performed receiver operating characteristic curve analysis to assess the predictive ability of the inflammation index. Results: Among a total of 71 patients, the median PFS was 5.5 months and the median OS was 9.5 months. The ORR and disease control rate were 16.9% and 84.5%, respectively. According to univariate and multivariate analyses, absolute neutrophil count (ANC) was the only indicator associated with both PFS (hazard ratio [HR] =1.095, 95% confidence interval [CI] 1.030-1.163, P=0.003) and OS (HR=1.057, 95% CI 1.003-1.113, P=0.037). In the group with ANC [greater than or equal to]4.58, the ORR was relatively lower (8.1% vs 26.5%, P=0.057), but not statistically significant; PFS and OS were relatively shorter (median PFS 5.0 [95% CI 4.4-9.6] vs 7.0 months [95% CI 4.4-5.7], P=0.024 and median OS 7.3 [95% CI 4.7-10.0] vs 17.6 months [95% CI 12.3-22.9], P < 0.001). ANC had a relatively high discriminatory ability to predict 10-month survival, with an area under the curve of 0.729, sensitivity of 82.5%, and specificity of 67.7%. Conclusion: Elevated pre-treatment ANC was associated with a poor prognosis. Patients with lower peripheral blood levels of ANC might benefit from anlotinib. Keywords: lung cancer, anlotinib, absolute neutrophil count, progression-free survival, overall survival Anlotinib is a multi-targeted tyrosine kinase inhibitor that inhibits tumor angiogenesis and cell proliferation. It is widely used as a third-line therapy for lung cancer. However, reliable prognostic biomarkers for predicting the efficacy of anlotinib are lacking. We conducted a retrospective study to investigate the prognostic value of serological inflammatory biomarkers in anlotinib treatment. Patients with advanced lung cancer treated with anlotinib monotherapy were enrolled. Cox regression was conducted to analyze the significant factors related to progression-free survival (PFS) and overall survival (OS). The objective response rate (ORR) was compared based on the median cut-off value of the significant inflammation index. Meanwhile, we created survival curves to compare the two groups and performed receiver operating characteristic curve analysis to assess the predictive ability of the inflammation index. Among a total of 71 patients, the median PFS was 5.5 months and the median OS was 9.5 months. The ORR and disease control rate were 16.9% and 84.5%, respectively. According to univariate and multivariate analyses, absolute neutrophil count (ANC) was the only indicator associated with both PFS (hazard ratio [HR] =1.095, 95% confidence interval [CI] 1.030-1.163, P=0.003) and OS (HR=1.057, 95% CI 1.003-1.113, P=0.037). In the group with ANC ≥4.58, the ORR was relatively lower (8.1% vs 26.5%, P=0.057), but not statistically significant; PFS and OS were relatively shorter (median PFS 5.0 [95% CI 4.4-9.6] vs 7.0 months [95% CI 4.4-5.7], P=0.024 and median OS 7.3 [95% CI 4.7-10.0] vs 17.6 months [95% CI 12.3-22.9], P < 0.001). ANC had a relatively high discriminatory ability to predict 10-month survival, with an area under the curve of 0.729, sensitivity of 82.5%, and specificity of 67.7%. Elevated pre-treatment ANC was associated with a poor prognosis. Patients with lower peripheral blood levels of ANC might benefit from anlotinib. Rong Chen,1,2,* Fang-Ying Lu,1,2,* Bing Liu,1,2 Jingwen Huang,1,2 Min Zhou,1,2 Ranran Dai,1,2 Yi Guo1,2 1Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China; 2Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China*These authors contributed equally to this workCorrespondence: Yi Guo; Ranran DaiDepartment of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Rui Jin 2nd Road, Shanghai, 200025, People's Republic of ChinaTel +86 131 6622 1556; Tel +86 131 6622 1556Fax +86 21 6467 4301Email guoyi621@qq.com; drr11154@rjh.com.cnPurpose: Anlotinib is a multi-targeted tyrosine kinase inhibitor that inhibits tumor angiogenesis and cell proliferation. It is widely used as a third-line therapy for lung cancer. However, reliable prognostic biomarkers for predicting the efficacy of anlotinib are lacking. We conducted a retrospective study to investigate the prognostic value of serological inflammatory biomarkers in anlotinib treatment.Patients and Methods: Patients with advanced lung cancer treated with anlotinib monotherapy were enrolled. Cox regression was conducted to analyze the significant factors related to progression-free survival (PFS) and overall survival (OS). The objective response rate (ORR) was compared based on the median cut-off value of the significant inflammation index. Meanwhile, we created survival curves to compare the two groups and performed receiver operating characteristic curve analysis to assess the predictive ability of the inflammation index.Results: Among a total of 71 patients, the median PFS was 5.5 months and the median OS was 9.5 months. The ORR and disease control rate were 16.9% and 84.5%, respectively. According to univariate and multivariate analyses, absolute neutrophil count (ANC) was the only indicator associated with both PFS (hazard ratio [HR] =1.095, 95% confidence interval [CI] 1.030- 1.163, P=0.003) and OS (HR=1.057, 95% CI 1.003- 1.113, P=0.037). In the group with ANC ≥ 4.58, the ORR was relatively lower (8.1% vs 26.5%, P=0.057), but not statistically significant; PFS and OS were relatively shorter (median PFS 5.0 [95% CI 4.4- 9.6] vs 7.0 months [95% CI 4.4- 5.7], P=0.024 and median OS 7.3 [95% CI 4.7- 10.0] vs 17.6 months [95% CI 12.3- 22.9], P < 0.001). ANC had a relatively high discriminatory ability to predict 10-month survival, with an area under the curve of 0.729, sensitivity of 82.5%, and specificity of 67.7%.Conclusion: Elevated pre-treatment ANC was associated with a poor prognosis. Patients with lower peripheral blood levels of ANC might benefit from anlotinib.Keywords: lung cancer, anlotinib, absolute neutrophil count, progression-free survival, overall survival |
| Audience | Academic |
| Author | Chen, Rong Liu, Bing Huang, Jingwen Lu, Fang-Ying Zhou, Min Guo, Yi Dai, Ranran |
| Author_xml | – sequence: 1 givenname: Rong surname: Chen fullname: Chen, Rong – sequence: 2 givenname: Fang-Ying surname: Lu fullname: Lu, Fang-Ying – sequence: 3 givenname: Bing surname: Liu fullname: Liu, Bing – sequence: 4 givenname: Jingwen orcidid: 0000-0002-5233-9693 surname: Huang fullname: Huang, Jingwen – sequence: 5 givenname: Min surname: Zhou fullname: Zhou, Min – sequence: 6 givenname: Ranran surname: Dai fullname: Dai, Ranran – sequence: 7 givenname: Yi surname: Guo fullname: Guo, Yi |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33976572$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkktvEzEUhUeoiD5gxxqNxIZFE8ZvzwYpRAUqBYigrC2P507iaGKntgfEv8dDUmiqypJt2d891rk-58WJ8w6K4iWqphhR8Xb-efZt-p1UgnD5pDhDSNQTRDA-ubc_Lc5j3FQVrxGhz4pTQmrBmcBnRZw10fdDgvILDCn43dr25dwPLpXWlWkN5RKC3a0h6L5833vflssArTUp5o1fOR9tHNHF4FblXDsDoVzqZMFl4iaATtCWv2xalzPX-2SdbZ4XTzvdR3hxWC-KHx-ubuafJouvH6_ns8XEMMrSpGVGkEo2nekq3AgNILimDWJNK9q6ZsCpMVIS1AAhvOEMQNY4YxoRoJqQi-J6r9t6vVG7YLc6_FZeW_X3wIeV0iFZ04PikhiO82SQpLWhumoYMpQAYrzVLc9a7_Zau6HZQmuyvdyRI9HjG2fXauV_KokqTpnIAm8OAsHfDhCT2tpooO-1Az9EhRnmiEhC64y-foBu_BBcbtVIScxqSfl_aqWzAes6n981o6iacUErgSs69mD6CJVHC1trcpI6m8-PCl7dN_rP4V1kMoD3gAk-xgCdMjblD_ejb9srVKkxl2rMpTrkMhddPii6030U_wNPleM5 |
| CitedBy_id | crossref_primary_10_1177_11772719251319641 crossref_primary_10_1111_1759_7714_14819 crossref_primary_10_1166_jbt_2022_3101 crossref_primary_10_1016_j_heliyon_2024_e24804 crossref_primary_10_1007_s12094_024_03558_6 |
| Cites_doi | 10.1158/1078-0432.CCR-14-2748 10.1016/j.ejca.2009.01.023 10.1158/1078-0432.CCR-13-1066 10.1016/j.ejca.2010.02.020 10.1053/rmed.2002.1328 10.1186/s13045-018-0664-7 10.1080/0284186X.2017.1415460 10.1016/j.ejca.2011.09.001 10.1016/j.jtho.2015.10.008 10.1007/s00432-014-1714-3 10.4161/cbt.24425 10.1055/s-2004-822974 10.3322/caac.21660 10.1111/1759-7714.13120 10.7150/jca.30478 10.1111/cas.13536 10.1038/sj.bjc.6602419 10.1016/j.lungcan.2017.01.013 10.1001/jamaoncol.2018.3039 10.1038/bjc.2017.478 10.1016/j.lungcan.2015.03.020 10.1016/j.cllc.2018.04.008 10.3978/j.issn.2218-6751.2015.06.09 10.1097/MOH.0b013e3283386660 10.3389/fimmu.2019.02155 10.1007/s00432-019-03064-1 10.20892/j.issn.2095-3941.2018.0158 10.1007/978-3-319-24223-1_1 10.1016/j.ctrv.2017.05.005 |
| ContentType | Journal Article |
| Copyright | 2021 Chen et al. COPYRIGHT 2021 Dove Medical Press Limited 2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2021 Chen et al. 2021 Chen et al. |
| Copyright_xml | – notice: 2021 Chen et al. – notice: COPYRIGHT 2021 Dove Medical Press Limited – notice: 2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2021 Chen et al. 2021 Chen et al. |
| DBID | AAYXX CITATION NPM 3V. 7X7 7XB 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. M0S M2O MBDVC PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.2147/CMAR.S307368 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central (New) ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest research library Research Library (Corporate) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College Research Library (Alumni Edition) ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Research Library ProQuest Central (New) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Chen et al |
| EISSN | 1179-1322 |
| EndPage | 3627 |
| ExternalDocumentID | oai_doaj_org_article_683c6283cc1849c4a0b51c43e156dad6 PMC8106457 A674072043 33976572 10_2147_CMAR_S307368 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: ; |
| GroupedDBID | --- 0YH 29B 2WC 53G 5VS 7X7 8FI 8FJ 8G5 AAYXX ABUWG ACGFO ADBBV ADRAZ AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BPHCQ BVXVI C1A CCPQU CITATION DIK DWQXO E3Z EBD F5P FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HMCUK HYE IAO IHR IPNFZ ITC KQ8 M2O M48 M~E O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RIG RNS RPM TDBHL TR2 UKHRP VDV NPM PMFND 3V. 7XB 8FK K9. MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c545t-d5c7308bfcf02b7aee76a4b15bd7d995e64cc8831be336b65ee892aeea13e4a33 |
| IEDL.DBID | M48 |
| ISSN | 1179-1322 |
| IngestDate | Wed Aug 27 01:17:34 EDT 2025 Thu Aug 21 14:01:39 EDT 2025 Fri Jul 11 05:27:12 EDT 2025 Sun Jun 29 13:49:35 EDT 2025 Tue Jun 17 21:46:46 EDT 2025 Tue Jun 10 20:34:17 EDT 2025 Thu Apr 03 06:57:30 EDT 2025 Tue Jul 01 02:41:28 EDT 2025 Thu Apr 24 23:07:36 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | lung cancer overall survival anlotinib absolute neutrophil count progression-free survival |
| Language | English |
| License | http://creativecommons.org/licenses/by-nc/3.0 2021 Chen et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c545t-d5c7308bfcf02b7aee76a4b15bd7d995e64cc8831be336b65ee892aeea13e4a33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 These authors contributed equally to this work |
| ORCID | 0000-0002-5233-9693 |
| OpenAccessLink | https://doaj.org/article/683c6283cc1849c4a0b51c43e156dad6 |
| PMID | 33976572 |
| PQID | 2528259846 |
| PQPubID | 3933196 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_683c6283cc1849c4a0b51c43e156dad6 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8106457 proquest_miscellaneous_2526138349 proquest_journals_2528259846 gale_infotracmisc_A674072043 gale_infotracacademiconefile_A674072043 pubmed_primary_33976572 crossref_citationtrail_10_2147_CMAR_S307368 crossref_primary_10_2147_CMAR_S307368 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-01-01 |
| PublicationDateYYYYMMDD | 2021-01-01 |
| PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | New Zealand |
| PublicationPlace_xml | – name: New Zealand – name: Macclesfield |
| PublicationTitle | Cancer management and research |
| PublicationTitleAlternate | Cancer Manag Res |
| PublicationYear | 2021 |
| Publisher | Dove Medical Press Limited Taylor & Francis Ltd Dove Dove Medical Press |
| Publisher_xml | – name: Dove Medical Press Limited – name: Taylor & Francis Ltd – name: Dove – name: Dove Medical Press |
| References | Sung (ref1) 2021 Wang (ref19) 2018; 15 Nicholson (ref3) 2016; 11 Li (ref6) 2019; 10 Politi (ref4) 2015; 21 Mei (ref13) 2017; 58 Ferrara (ref25) 2010; 17 Lecot (ref20) 2019; 10 Sierko (ref29) 2004; 30 Keizman (ref23) 2012; 48 Sun (ref14) 2014; 140 Laird (ref12) 2013; 19 Han (ref8) 2018; 118 Xie (ref7) 2018; 109 Teramukai (ref21) 2009; 45 Torre (ref2) 2016; 893 Canna (ref27) 2005; 92 Han (ref9) 2018; 4 Zer (ref22) 2018; 19 Azam (ref24) 2010; 46 Wu (ref17) 2019; 10 Bagley (ref15) 2017; 106 Botta (ref16) 2013; 14 Chen (ref18) 2020; 146 Hall (ref5) 2015; 4 Shen (ref10) 2018; 11 Naqash (ref11) 2018; 57 Simmons (ref26) 2015; 88 Alexandrakis (ref28) 2002; 96 |
| References_xml | – volume: 21 start-page: 2213 year: 2015 ident: ref4 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-2748 – volume: 45 start-page: 1950 year: 2009 ident: ref21 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2009.01.023 – volume: 19 start-page: 5456 year: 2013 ident: ref12 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-1066 – volume: 46 start-page: 1323 year: 2010 ident: ref24 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2010.02.020 – volume: 96 start-page: 553 year: 2002 ident: ref28 publication-title: Respir Med doi: 10.1053/rmed.2002.1328 – volume: 11 start-page: 120 year: 2018 ident: ref10 publication-title: J Hematol Oncol doi: 10.1186/s13045-018-0664-7 – volume: 57 start-page: 867 year: 2018 ident: ref11 publication-title: Acta Oncol doi: 10.1080/0284186X.2017.1415460 – volume: 48 start-page: 202 year: 2012 ident: ref23 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2011.09.001 – volume: 11 start-page: 300 year: 2016 ident: ref3 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2015.10.008 – volume: 140 start-page: 1537 year: 2014 ident: ref14 publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-014-1714-3 – volume: 14 start-page: 469 year: 2013 ident: ref16 publication-title: Cancer Biol Ther doi: 10.4161/cbt.24425 – volume: 30 start-page: 95 year: 2004 ident: ref29 publication-title: Semin Thromb Hemost doi: 10.1055/s-2004-822974 – year: 2021 ident: ref1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21660 – volume: 10 start-page: 1590 year: 2019 ident: ref17 publication-title: Thorac Cancer doi: 10.1111/1759-7714.13120 – volume: 10 start-page: 5082 year: 2019 ident: ref6 publication-title: J Cancer doi: 10.7150/jca.30478 – volume: 109 start-page: 1207 year: 2018 ident: ref7 publication-title: Cancer Sci doi: 10.1111/cas.13536 – volume: 92 start-page: 651 year: 2005 ident: ref27 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6602419 – volume: 106 start-page: 1 year: 2017 ident: ref15 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2017.01.013 – volume: 4 start-page: 1569 year: 2018 ident: ref9 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2018.3039 – volume: 118 start-page: 654 year: 2018 ident: ref8 publication-title: Br J Cancer doi: 10.1038/bjc.2017.478 – volume: 88 start-page: 304 year: 2015 ident: ref26 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2015.03.020 – volume: 19 start-page: 426 year: 2018 ident: ref22 publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2018.04.008 – volume: 4 start-page: 515 year: 2015 ident: ref5 publication-title: Transl Lung Cancer Res doi: 10.3978/j.issn.2218-6751.2015.06.09 – volume: 17 start-page: 219 year: 2010 ident: ref25 publication-title: Curr Opin Hematol doi: 10.1097/MOH.0b013e3283386660 – volume: 10 start-page: 2155 year: 2019 ident: ref20 publication-title: Front Immunol doi: 10.3389/fimmu.2019.02155 – volume: 146 start-page: 401 year: 2020 ident: ref18 publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-019-03064-1 – volume: 15 start-page: 443 year: 2018 ident: ref19 publication-title: Cancer Biol Med doi: 10.20892/j.issn.2095-3941.2018.0158 – volume: 893 start-page: 1 year: 2016 ident: ref2 publication-title: Adv Exp Med Biol doi: 10.1007/978-3-319-24223-1_1 – volume: 58 start-page: 1 year: 2017 ident: ref13 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2017.05.005 |
| SSID | ssj0069134 |
| Score | 2.2291446 |
| Snippet | Anlotinib is a multi-targeted tyrosine kinase inhibitor that inhibits tumor angiogenesis and cell proliferation. It is widely used as a third-line therapy for... Purpose: Anlotinib is a multi-targeted tyrosine kinase inhibitor that inhibits tumor angiogenesis and cell proliferation. It is widely used as a third-line... Rong Chen,1,2,* Fang-Ying Lu,1,2,* Bing Liu,1,2 Jingwen Huang,1,2 Min Zhou,1,2 Ranran Dai,1,2 Yi Guo1,2 1Department of Respiratory and Critical Care Medicine,... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 3619 |
| SubjectTerms | absolute neutrophil count anlotinib Biomarkers Blood Cancer patients Cancer therapies Chemotherapy Comparative analysis Development and progression Drug dosages Growth factors Health aspects Kinases Lung cancer Lymphocytes Medical prognosis Medical records Medical research Medicine, Experimental Metastasis Mutation Neutrophils Original Research overall survival Patients Prognosis progression free survival Regression analysis Tumors Tyrosine |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9JLadOX26So0NJDcbO2HpaPztIQShOWNoHchF4mhsUOa-__74zsXdaU0ktvxhqDpfmk-cYefSLko1kwxYVhaWaykPK6ZGnpeZ0q6ZGdB2tDrLa4lpe3_PuduDs46gtrwkZ54HHgzqRiTkIMdA5ykdJxs7Aic5wFSDy88VFsG2LeLpka12C5-58McEsx3xpL3vFMnrPlVfXz6y-ENsqrHgSjqNn_58p8EJrmZZMHcejiGXk6EUhajS_-nDwK7TF5fDX9In9B-spGOAV6HbbDpnu4b9YUd54PtGkp0D26AtBFMYE1Pceydbra4NNDDxcd1t01PZr-gGWALhEUG7oa1Vd7eoMcM3iKn29p1a67oWkb-5LcXny7WV6m08kKqQPGNKReOJjZytauXuS2MCEU0nCbCesLX5YiSO6cUiyzgTFppQhBlTmYmYwFbhh7RY7arg1vCK0LaY0xyi5yzwNqy3iI-L5UrmaFFyYhX3ZDrN0kO46nX6w1pB_oEI0O0ZNDEvJpb_0wym38xe4cvbW3QZHseAOgoyfo6H9BJyGf0dcapzK8kjPTjgToGIpi6UoWKB-34CwhJzNLmIJu3rxDi56WgF7nArcFl8DvEvJh34xPYllbG7pttAE6pRgvE_J6BNe-SwyZoijyhBQz2M36PG9pm_soEK4yVCEs3v6PQXpHnuRYxhO_Op2Qo2GzDafAwwb7Pk6537HML4o priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gvgifls9JYLig9RrmzRJn2Rv8TjEOxa9g30r-epdYWnXtvv_m0mzdYvoW2km0HRmMr8kk98g9F4mRNBckjiVqY1pVZC4MLSKBTOAzq1S1mdbXLLza_ptna_Dhlsf0ir3c6KfqE2rYY_8JMvhlmXhwuWX7a8YqkbB6WoooXEX3QPqMkjp4utpwcXgVHlMdodqPCfLi8WPzz_BqIFY9SAMebb-v-fkg6A0T5g8iEBnj9DDAB3xYtT1Y3THNk_Q_YtwOP4U9QvlDcniS7sbunZ7W28w3DkfcN1gB_TwypmbpxHY4FNIWMerDnoPvXtoIeOu7kH0u5sA8BLMocOrkXe1x1eALq3BsHGLF82mHeqmVs_Q9dnXq-V5HGoqxNphpSE2uXY-LVSlqyRTXFrLmaQqzZXhpihyy6jWQpBUWUKYYrm1osicmEyJpZKQ5-ioaRv7EuGKMyWlFCrJDLXAKmNcrDeF0BXhJpcR-rT_xaUOhONQ92JTuoUHKKQEhZRBIRH6MElvR6KNf8idgrYmGaDH9i_a7qYM3lYyQTRzwElrt4AtNJWJylNNiXWrVSMNi9BH0HUJTuw-SctwF8ENDOiwygXjQByXUBKh45mkcz49b95bSxmcvy__mGqE3k3N0BMS2hrb7ryMA1KC0CJCL0bjmoZEACPmPIsQn5ndbMzzlqa-9dTgIgX-Qf7q_5_1Gj3IIDXH7yQdo6Oh29k3DlsN6q13oN_otyWb priority: 102 providerName: ProQuest |
| Title | Absolute Neutrophil Count in the Peripheral Blood Predicts Prognosis in Lung Cancer Patients Treated with Anlotinib |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33976572 https://www.proquest.com/docview/2528259846 https://www.proquest.com/docview/2526138349 https://pubmed.ncbi.nlm.nih.gov/PMC8106457 https://doaj.org/article/683c6283cc1849c4a0b51c43e156dad6 |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ba9swFD70AmMvY_d564IGG3sY7mJLluSHMZLQrowlhK6BvBndvBqC3TkObP9-Oo4TarrBXkywjiCSvmN9Rzr6BPBWDalkiaJhpCIXsjylYWpZHkpukZ07rV2bbTHjFwv2dZksD2B322jXgeu_hnZ4n9SiXp3--vn7s3f4T5jGHDHxcTIdXZ5-R7ByeQjHfk4S6KJTtt9P4Lv9ZQ-_EOOvbQr8ndq9yanV8L_7pb41VfXTKG_NS-cP4UFHKMloi4BHcODKx3Bv2m2ZP4H1SLfwcmTmNk1d3VwXK4In0RtSlMTTPzL3IGzFBVZkjGnsZF5j7Wbtf1SYh1es0fSb_yyQCYKkJvOtGuuaXCHndJbgci4ZlauqKcpCP4XF-dnV5CLsbloIjWdQTWgT4z1d6tzkw1gL5Zzgiuko0VbYNE0cZ8ZISSPtKOWaJ87JNPZmKqKOKUqfwVFZle4FkFxwrZSSehhb5lBrxnoGYFNpcipsogL4sOvizHQy5Hgbxirz4QgOSIYDknUDEsC7vfXNVn7jH3ZjHK29DYpmty-q-kfW-WDGJTXc0yljfFibGqaGOokMo87HsFZZHsB7HOsMweb_klHdCQXfMBTJykZcoJzckNEATnqW3iVNv3iHlmyH6CxO8Jhw6vleAG_2xVgT09xKV21aG0-vJGVpAM-34No3iSJzTEQcgOjBrtfmfklZXLeC4TJCVULx8j878xXcjzFzp11oOoGjpt641556NXoAh2IpBnA8PpvNLwftAoZ_fllGg9bf_gARhTBz |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLamTgJeEHcyBhiJiQcU1sSO4zwg1JZNHWuranTS3oJvYZGqpGtSIf4UvxGfXEojBG97q-oTKc65fbaPv4PQW9EnnAaCuJ7wjEuTiLiRponLmQZ0bqQ0VbXFjI0v6Zer4GoP_WrvwkBZZRsTq0CtcwV75Md-ALcsI5suP61uXOgaBaerbQuN2izOzc8fdslWfDz7bPV75PunJ4vR2G26CrjKooXS1YGyVs1lopK-L0NhTMgElV4gdaijKDCMKsU58aQhhEkWGMMj34oJjxgqYAPUhvx9SuxSpof2hyez-UUb-xmcY9fl9dD_53g0HVx8-ApuBFSuO4mv6g_wdxbYSYPdEs2dnHf6AN1vwCoe1Nb1EO2Z7BG6M22O4x-jYiAr0zV4ZjblOl9dp0sMt9xLnGbYQks8twZeERcs8RBK5PF8DU-Xhf2RQ41fWoDoxIYcPAIDXON5zfRa4AXgWaMxbBXjQbbMyzRL5RN0eSvf-ynqZXlmniOchEwKIbjs-5oa4LHRFl3oiKuEhDoQDnrffuJYNRTn0GljGdulDigkBoXEjUIcdLSVXtXUHv-QG4K2tjJAyF39ka-_x41_x4wTxSxUU8oumSNFRV8GnqLE2PWxFpo56B3oOoawYV9Jieb2g50YEHDFAxYCVV2fEgcddiStu6vucGstcRNuiviPczjozXYYnoQSuszkm0rGQjdOaOSgZ7VxbadEAJUGoe-gsGN2nTl3R7L0uiIj5x4wHoYH_3-t1-jueDGdxJOz2fkLdM-HwqBqH-sQ9cr1xry0yK6Urxp3wujbbXvwb57YZY4 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5VRaq4IN4YCiwSFQdkGnufPiCUpkQtbaMIWik3sy9TS5EdYkeIv8avY8d2QiwEt96i7Fjyel7f7s5-g9BrNSCSMkXCSEUupFlCwsTSLJTcAjp3Wrum2mLCT67opxmb7aBf67swUFa5jolNoLalgT3yw5jBLcvEp8vDrCuLmB6PPyy-h9BBCk5a1-00WhM5cz9_-OVb9f702Ov6II7HHy9HJ2HXYSA0HjnUoWXGW7jUmckGsRbKOcEV1RHTVtgkYY5TY6QkkXaEcM2ZczKJvZiKiKMKNkN9-L8lCIvAx8Rss9jjcKLdFtpDJ6DD0cXw87sv4FBA6rqVAptOAX_ng62E2C_W3Mp-47voTgdb8bC1s3toxxX30d5FdzD_AFVD3RixwxO3qpfl4jqfY7jvXuO8wB5k4qk39YbCYI6PoFgeT5fwdF35HyVU--UViJ774INHYIpLPG05Xyt8CcjWWQybxnhYzMs6L3L9EF3dyNd-hHaLsnBPEM4E10opqQexpQ4YbazHGTaRJiPCMhWgt-tPnJqO7Bx6bsxTv-gBhaSgkLRTSIAONtKLluTjH3JHoK2NDFBzN3-Uy29p5-kpl8RwD9qM8YvnxFA10CwylDi_UrbK8gC9AV2nEED8KxnV3YPwEwMqrnTIBZDWDSgJ0H5P0ju-6Q-vrSXtAk-V_nGTAL3aDMOTUExXuHLVyHgQJwlNAvS4Na7NlAjgUybiAIme2fXm3B8p8uuGllxGwH0onv7_tV6iPe-36fnp5OwZuh1DhVCzobWPduvlyj33EK_WLxpfwujrTTvvbwpVaF4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Absolute+Neutrophil+Count+in+the+Peripheral+Blood+Predicts+Prognosis+in+Lung+Cancer+Patients+Treated+with+Anlotinib&rft.jtitle=Cancer+management+and+research&rft.au=Chen%2C+Rong&rft.au=Lu%2C+Fang-Ying&rft.au=Liu%2C+Bing&rft.au=Huang%2C+Jingwen&rft.date=2021-01-01&rft.issn=1179-1322&rft.eissn=1179-1322&rft.volume=13&rft.spage=3619&rft.epage=3627&rft_id=info:doi/10.2147%2FCMAR.S307368&rft.externalDBID=n%2Fa&rft.externalDocID=10_2147_CMAR_S307368 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1179-1322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1179-1322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1179-1322&client=summon |